TASAKI Yoshikazu 田崎嘉一

… Alternative Names

田崎嘉一タサキヨシカズ

Less

Researcher Number	60374807
Other IDs
Affiliation (Current)	2025: 旭川医科大学, 大学病院, 教授
Affiliation (based on the past Project Information) *help	2025: 旭川医科大学, 大学病院, 教授 2022 – 2023: 旭川医科大学, 大学病院, 教授 2013 – 2021: 旭川医科大学, 医学部, 教授 2010 – 2012: 旭川医科大学, 医学部, 准教授 2005: Asahikawa Med.College, Department of Hospital Pharm.acy, 医学部, 助教授
Review Section/Research Field	Principal Investigator Basic Section 47060:Clinical pharmacy-related / Medical pharmacy Except Principal Investigator Basic Section 47060:Clinical pharmacy-related / Basic Section 59010:Rehabilitation science-related / Medical pharmacy
Keywords	Principal Investigator パーキンソン病進行抑制薬 / Akt / 細胞死抑制 / meloxicam誘導体 / meloxicam / オキシカム系NSAIDs / オキシカム系NSAIDｓ / 神経細胞死抑制 / パーキンソン病 / Aｋｔ … More / 新規抗パーキンソン病薬 / 新規治療薬候補 / meloxicam誘導体の開発 / ドラッグリポジショニング / POC試験 / 神経細胞死 / 新規パーキンソン病治療薬 / 進行抑制薬 / mTOR / TrkA / 神経細胞死抑制薬 / 細胞生存シグナル / ドラッグリプロファイリング / 新規進行抑制薬 / メロキシカム / オキシカム系非ステロイド性抗炎症薬 / パーキンソン病治療薬 / 新規治療薬 / PI3kinase/Akt経路 / 新規メカニズム / シグナル伝達 / NSAIDｓ / オキシカム系 / 臨床薬学 … More Except Principal Investigator 抗菌薬 / 薬剤性腎障害 / ドラッグリポジショニング / ビッグデータ / 尿細管保護薬 / 介護システム / オンライン診療 / リハビリテーション / 転倒予防遠隔リハビリテーション / ICT / IoT / リアビリテーション / 遠隔医療 / basal ganglia / extrapyramidal system / Tandospirone / 5-HT1A receptor agonist / Parkinson disease / ラット / 5HT1A受容体作動薬 / マイクロダイアリシス / グルタミン醜 / 片側パーキンソン病モデル / 細胞死 / 保護効果 / SH-SY5Y細胞 / 5HT1A受容体作動 / 基底核 / 錐体外路 / タンドスピロン / 5HT1A受容体作動薬物 / パーキンソン病 Less

Elucidation of the mechanism of action for the development of new drugs for the treatment of Parkinson's diseasePrincipal Investigator
- Principal Investigator
  
  田崎嘉一
- Project Period (FY)
  2025 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Asahikawa Medical College
ビッグデータの融合解析を基盤にした尿細管保護薬の開発
- Principal Investigator
  
  中馬真幸
- Project Period (FY)
  2023 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Asahikawa Medical College
Acquisition of candidate compounds as novel disease-modifying antiparkinsonian drugs for clinical trialPrincipal Investigator
- Principal Investigator
  
  田崎嘉一
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Asahikawa Medical College
Development of novel neuroprotective oxicam derivatives for the treatment of Parkinson's diseasePrincipal Investigator
- Principal Investigator
  
  Tasaki Yoshikazu
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Asahikawa Medical College
Establishment of care system using telemedicine in medical depopulated areas
- Principal Investigator
  
  吉田晃敏
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 59010:Rehabilitation science-related
- Research Institution
  Asahikawa Medical College
Preclinical Proof-of-Concent research targeting development of novel neuroprotective drugs for Pankinson's disease.Principal Investigator
- Principal Investigator
  
  Tasaki Yoshikazu
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Asahikawa Medical College
Development of the antiparkinsonian drug with novel mechanism by drug-reprofiling.Principal Investigator
- Principal Investigator
  
  TASAKI YOSHIKAZU
- Project Period (FY)
  2013 – 2015
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Asahikawa Medical College
Development of oxicam-bearing non-steroidal anti-inflammatory drugs with novel anti-parkinsonian mechanism.Principal Investigator
- Principal Investigator
  
  TASAKI Yoshikazu
- Project Period (FY)
  2010 – 2012
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Asahikawa Medical College
5-HT1A agonists, ameliorate movement disorder via non-dopaminergic systems in Parkinson's patients.
- Principal Investigator
  
  MATSUBARA Kazuo
- Project Period (FY)
  2003 – 2005
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Asahikawa Medical College

All 2023 2019 2013 2012 2011 2010 2006

All Journal Article Presentation Patent

[Journal Article] The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease2023
- Author(s)
  Manabe T, Iwayama K, Chuma M, Tasaki Y, Matsumoto S.
- Journal Title
  
  In Vivo
  
  Volume: 37 Issue: 3 Pages: 1260-1265
- DOI
  10.21873/invivo.13203
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K06208
[Journal Article] Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases2023
- Author(s)
  Bando T, Chuma M, Hamano H, Niimura T, Okada N, Kondo M, Izumi Y, Ishida S, Yoshioka T, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Izawa-Ishizaka Y, Azuma M, Yanagawa H, Tasaki Y, Ishizawa K.
- Journal Title
  
  Acta Medica Okayama
  
  Volume: 77 Issue: 6 Pages: 595-605
- DOI
  10.18926/AMO/66151
- URL
  https://ousar.lib.okayama-u.ac.jp/66151
- Language
  English
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K06208
[Journal Article] メロキシカムは,マウスパーキンソン病モデルにおいて,Aktシグナル維持により運動障害とドパミン神経変性を改善する2013
- Author(s)
  田崎嘉一,山本譲,大村友博,坂口智己,木村周古,大滝康一,小野尚志,須野学,浅利優,大久保知子,野田敏宏,粟屋敏雄,清水惠子,松原和夫.
- Journal Title
  
  北海道医学雑誌
  
  Volume: 88(1) Pages: 45-45
- NAID
  10031148191
- Data Source
  KAKENHI-PROJECT-22590129
[Journal Article] Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.2012
- Author(s)
  Tasaki Y, Yamamoto J, Omura T, Sakaguchi T, Kimura N, Ohtaki K, Ono T, Suno M, Asari M, Ohkubo T, Noda T, Awaya T, Shimizu K, Matsubara K.
- Journal Title
  
  Neurosci Lett
  
  Volume: 521 Issue: 1 Pages: 15-19
- DOI
  10.1016/j.neulet.2012.05.045
- NAID
  120006522757
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22590129, KAKENHI-PROJECT-23590841, KAKENHI-PROJECT-23790722, KAKENHI-PROJECT-24590176
[Journal Article] Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4- phenyl, pyridinium-induced cytotoxicity.2012
- Author(s)
  Tasaki Y, Yamamoto J, Omura T, Noda T, Kamiyama N, Yoshida K, Satomi M, Sakaguchi T, Asari M, Ohkubo T, Shimizu K, Matsubara K.
- Journal Title
  
  Eur J Pharmacol.
  
  Volume: 676 Issue: 1-3 Pages: 57-63
- DOI
  10.1016/j.ejphar.2011.11.046
- NAID
  120006522756
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22590129, KAKENHI-PROJECT-23590841, KAKENHI-PROJECT-23790722
[Journal Article] Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl-pyridinium-induced cytotoxicity2012
- Author(s)
  Y.Tasaki, et al.
- Journal Title
  
  European Journal of Pharmacology
  
  Volume: 676 Pages: 57-63
- NAID
  120006522756
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22590129
[Journal Article] Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y2010
- Author(s)
  Tasaki Y, Omura T, Yamada T, Ohkubo T, Suno M, Iida S, Sakaguchi T, Asari M, Shimizu K, Matsubara K.
- Journal Title
  
  cells.
  
  Volume: 1344 Pages: 25-33
- DOI
  10.1016/j.brainres.2010.04.085
- Data Source
  KAKENHI-PROJECT-22590129
[Journal Article] Meoxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxici ty via the phosphatidylinositol 3-kinase/Akt pathway in human dopamin ergic neuroblastoma SH-SY5Y cells2010
- Author(s)
  Tasaki, et al.
- Journal Title
  
  Brain Research
  
  Volume: 1344 Pages: 25-33
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22590129
[Journal Article] Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.2006
- Author(s)
  K.Matsubara, K Shimizu, M Suno, K.Ogawa, T.Awaya, T.Yamada, T.Noda, M.Satomi, K.Ohtaki, K.Chiba, Y.Tasaki, H.Shiono
- Journal Title
  
  Brain Research (in press)
- Description
  「研究成果報告書概要(欧文)」より
- Data Source
  KAKENHI-PROJECT-15590121
[Journal Article] Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions2006
- Author(s)
  K.Matsubara, Y.Tasaki et al.
- Journal Title
  
  Brain Research (in press)
- Data Source
  KAKENHI-PROJECT-15590121
[Patent] PCT2019
- Inventor(s)
  田崎嘉一、増野匡彦、大江知之、高橋恭子
- Industrial Property Rights Holder
  田崎嘉一、増野匡彦、大江知之、高橋恭子
- Industrial Property Rights Type
  特許
- Filing Date
  2019
- Overseas
- Data Source
  KAKENHI-PROJECT-19K07186
[Patent] PCT2019
- Inventor(s)
  田崎嘉一、増野匡彦、大江知之、高橋恭子
- Industrial Property Rights Holder
  田崎嘉一、増野匡彦、大江知之、高橋恭子
- Industrial Property Rights Type
  特許
- Filing Date
  2019
- Overseas
- Data Source
  KAKENHI-PROJECT-19K07186
[Patent] 新規化合物を含むパーキンソン病治療薬2019
- Inventor(s)
  田崎嘉一ほか
- Industrial Property Rights Holder
  田崎嘉一ほか
- Industrial Property Rights Type
  特許
- Filing Date
  2019
- Data Source
  KAKENHI-PROJECT-16K08389
[Presentation] Identification of prophylactic drug for vancomycin- associated nephrotoxicity using big data analysis2023
- Author(s)
  Chuma M, Goda M, Zamami Y, Takechi K, Hamano H, Ishida S, Niimura T, Kondo M, Bando T, Izawa-Ishizawa Y, Tasaki Y, Ishizawa K
- Organizer
  19th World Congress of Basic & Clinical Pharmacology (WCP2023)
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K06208
[Presentation] ステロイドはバンコマイシン関連腎障害を予防する― ビッグデータ解析・基礎研究・臨床研究の統合による検討 ―2023
- Author(s)
  中馬真幸, 合田光寛, 座間味義人, 濱野裕章, 武智研志, 石田俊介, 坂東貴司, 新村貴博, 近藤正輝, 石澤有紀, 田崎嘉一, 石澤啓介.
- Organizer
  第44回日本臨床薬理学会学術総会/第97回日本薬理学会年会
- Data Source
  KAKENHI-PROJECT-23K06208
[Presentation] Mammalian target of rapamycin (mTOR) mediates neuroprotection by oxicam nonsteroidal　anti-inflammatory drugs against MPP+-induced SH-SY5Y cell death.2013
- Author(s)
  Y. Tasaki, J. Yamamoto, T. Ohkubo, T. Noda, T. Omura, T. Ono, M. Suno, T. Sakaguchi, and K. Matsubara.
- Organizer
  Sfn(Society for Neuroscience) 2013
- Place of Presentation
  Ｓan diego（米国）
- Data Source
  KAKENHI-PROJECT-25460204
[Presentation] Myeloid cell leukemia-1(Mcl-1) はSH-SY5Y細胞のMPP+誘発アポトーシスに対して保護作用を持つ2013
- Author(s)
  田崎嘉一
- Organizer
  日本薬学会第133回年会
- Place of Presentation
  横浜
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] Myeloid cell leukemia-1 (Mcl-1)はSH-SY5Y細胞のMPP+誘発アポトーシスに対して保護作用を持つ2013
- Author(s)
  田崎嘉一
- Organizer
  日本薬学会第133年会
- Place of Presentation
  横浜
- Year and Date
  2013-03-28
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] Oxicam non-steroidal anti-inflammatory drugs ameliorate motor dysfunction and dopaminergic degeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.2012
- Author(s)
  Tasaki Y, Yamamoto J, Ohkubo T, Noda T, Omura T, Onoa T., Kimura N., Suno M., T. Sakaguchi, and Matsubara K
- Organizer
  Neuroscience 2012
- Place of Presentation
  シカゴ,米国
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] オキシカム系NSAIDsは、MPTP反復投与パーキンソン病モデルにおいて黒質線条体神経を保護し、行動異常を改善する2012
- Author(s)
  田崎嘉一
- Organizer
  日本薬学会第132年会
- Place of Presentation
  札幌
- Year and Date
  2012-03-30
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] オキシカム系NSAIDsは、MPTP反復投与パーキンソン病モデルにおいて黒質線条体神経を保護し、行動異常を改善する.2012
- Author(s)
  田崎嘉一ら
- Organizer
  日本薬学会第132年会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] Oxicam non-steroidal anti-inflammatory drugs ameliorate motor dysfunction and dopaminergic degeneration by maintaining Akt-signaling in a mouse Parkinson’s disease model.2012
- Author(s)
  Tasaki Y
- Organizer
  Society for Neuroscience 2012
- Place of Presentation
  ニューオーリンズ
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] オキシカム系NSAIDsによる神経細胞死抑制作用はAkt/mTOR経路を介する2011
- Author(s)
  田崎嘉一ら
- Organizer
  日本薬学会第131年会
- Place of Presentation
  静岡
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] Structural specificity of Akt-mediated neuroprotection by oxicam non-steroidal anti-inflammatory drugs against 1-methyl-4-phenyl pyridinium-induced cell death2011
- Author(s)
  Y.Tasaki, et al., (田崎嘉一, ら)
- Organizer
  XIX World Congress on Parkinson's Disease and Related Disorders
- Place of Presentation
  Shanghai, China
- Year and Date
  2011-12-14
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] オキシム系NSAIDsによる神経細胞死抑制作用は、Akt/MTOR経路を介する2011
- Author(s)
  田崎, ら
- Organizer
  第131回薬学会年会
- Place of Presentation
  静岡(年会自体は中止、実績にはなるとのこと)
- Year and Date
  2011-03-29
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] オキシカム系非ステロイド性抗炎症薬(NSAIDs)の新規抗パーキンソン病作用2011
- Author(s)
  田崎嘉一
- Organizer
  医療薬学フォーラム2011
- Place of Presentation
  旭川(招待講演)
- Year and Date
  2011-07-10
- Data Source
  KAKENHI-PROJECT-22590129
[Presentation] Structural specificity of Akt-mediated neuroprotection by oxicam non- steroidal anti-inflammatory drugs against 1-methyl-4-phenyl pyridinium- induced cell death2011
- Author(s)
  Tasaki Y, Yamamoto J, Omura T, Noda T, Kamiyama N, Yoshida K, Satomi M, Sakaguchi T, Asari T, Ohkubo T, Shimizu K and Matsubara K
- Organizer
  PDRD
- Place of Presentation
  上海,中国
- Data Source
  KAKENHI-PROJECT-22590129

1. MATSUBARA Kazuo (20127533)

# of Collaborated Projects: 2 results

# of Collaborated Products: 8 results
2. Kamiyama Naoya (20431398)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
3. FUKUDO Masahide (60437233)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. SHIMIZU Keiko (90312462)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. 吉田晃敏 (70125417)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 服部ユカリ (00272899)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 大田哲生 (20233132)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 竹川政範 (50216876)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. 盛一健太郎 (70455715)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
10. 藤谷幹浩 (80322915)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
11. 山根由起子 (80745282)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
12. 中馬真幸 (20819289)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
13. 眞鍋貴行 (60460698)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
14. 清水惠子

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

TASAKI Yoshikazu 田崎 嘉一

田崎 嘉一 タサキ ヨシカズ

Research Projects

Research Products

Co-Researchers

Elucidation of the mechanism of action for the development of new drugs for the treatment of Parkinson's diseasePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

ビッグデータの融合解析を基盤にした尿細管保護薬の開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Acquisition of candidate compounds as novel disease-modifying antiparkinsonian drugs for clinical trialPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of novel neuroprotective oxicam derivatives for the treatment of Parkinson's diseasePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Establishment of care system using telemedicine in medical depopulated areas

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Preclinical Proof-of-Concent research targeting development of novel neuroprotective drugs for Pankinson's disease.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of the antiparkinsonian drug with novel mechanism by drug-reprofiling.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of oxicam-bearing non-steroidal anti-inflammatory drugs with novel anti-parkinsonian mechanism.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

5-HT1A agonists, ameliorate movement disorder via non-dopaminergic systems in Parkinson's patients.

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases2023

Author(s)

Journal Title

DOI

URL

Language

Data Source

[Journal Article] メロキシカムは,マウスパーキンソン病モデルにおいて,Aktシグナル維持により運動障害とドパミン神経変性を改善する2013

Author(s)

Journal Title

NAID

Data Source

[Journal Article] Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.2012

Author(s)

Journal Title

DOI

TASAKI Yoshikazu 田崎嘉一

田崎嘉一タサキヨシカズ

[Presentation] Mammalian target of rapamycin (mTOR) mediates neuroprotection by oxicam nonsteroidal　anti-inflammatory drugs against MPP+-induced SH-SY5Y cell death.2013